TGF-β1 level in platelet-rich plasma in patients with diseases and injuries of the musculoskeletal system

Ye. Goliuk; V. Yavorovska; N. Bezdeneznykh; T. Kozak; K. Saulenko

doi:10.22494/cot.v7i2.104

Ye. Goliuk The Scientific and Practice Center of Tissue and Cellular Therapy, State Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
V. Yavorovska Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kyiv, Ukraine
N. Bezdeneznykh Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Kyiv, Ukraine
T. Kozak Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Kyiv, Ukraine
K. Saulenko The Scientific and Practice Center of Tissue and Cellular Therapy, State Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

DOI: https://doi.org/10.22494/cot.v7i2.104

Keywords: platelet-rich plasma, TGF-β1, diseases of the musculoskeletal system

Abstract

Platelet-rich plasma (PRP) is plasma with high concentration of platelets compared with whole blood. The therapeutic effect of platelet-rich plasma based on the effect of growth factors contained in α-granules of platelets. Transforming growth factor β1 (TGF-β1) is a growth factor of TGF-β superfamily which an amount is considerable in platelets and have the important role in musculoskeletal system regeneration.
Materials and methods. In this study using the ELISA, we determined the content of TGF-β1 in platelet-rich plasma in 14 patients with various musculoskeletal disorders, aged from 21 to 79.
Results. The level of TGF-β1 in platelet-rich plasma was found to be 194.57 ± 25.76 ng/ml, which was 30 times higher than its control content (platelet-poor plasma), where its content was 6.52 ± 3.26 ng/ml. No statistically significant difference was observed between TGF-β1 levels in platelet-rich plasma in the patients of different age and gender.
Conclusions. It has been established that platelet-rich plasma can serve as a source of TGF-β1 for therapeutic purposes. TGF-β1 content in platelet-rich plasma has been shown to be independent of gender and age and, therefore, a wide range of patients may be treated with it.

References

Alsousou J, Thompson M, Hulley P. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery. J Bone Joint Surg. 2009; 91(8):987-996. DOI: 10.1302/0301-620X.91B8.22546.

Alves R, Grimalt R. A review of platelet-rich plasma: History, Biology, mechanism of action, and classification. Skin Appendage Disord. 2018; 4(1):18-24. DOI: 10.1159/000477353.

Anitua E, Orive G. Clinical outcome of immediately loaded dental implants bioactivated with plasma rich in growth factors: a 5-year retrospective study. J Periodontol. 2008; 79(7): 1168-1176. DOI:10.1902/jop.2010.090637.

Araki J, Jona M, Eto H. Optimized preparation method of platelet-concentrated plasma and noncoagulating plateletderived factor concentrates: maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods. 2012; 18(3):176-85. DOI: 10.1089/ten.TEC.2011.0308.

Assirelli E, Filardo G. Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surg Sports Traumatol Arthrosc. 2015; 23(9):2690-2703. DOI: 10.1007/s00167-014-3113-3.

van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Does TGF-beta protect articular cartilage in vivo? Agents Actions Suppl. 1993; 39:27-131. DOI:10.1007/978-3-0348-7442-7_14.

Crane JL, Xian L, Cao X. Role of TGF-β signaling in coupling bone remodeling. Methods Mol Biol. 2016; 1344:287-300. DOI:10.1007/978-1-4939-2966-5_18.

Dahlgren LA, Mohammed HO, Nixon AJ. Temporal expression of growth factors and matrix molecules in healing tendon lesions. J Orthop Res. 2005; 23(1):84. https://doi.org/10.1016/j.orthres.2004.05.007.

Dawood AS, Salem HA. Current clinical applications of platelet-rich plasma in various gynecological disorders: An appraisal of theory and practice. Clin Exp Reprod Med. 2018; 45(2):67-74. DOI: 10.5653/cerm.2018.45.2.67.

Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy - future or trend? Arthritis Res Ther. 2012; 14(4):219-229. DOI: 10.1186/ar3914.

Dohan Ehrenfest DM, Rasmusson L. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009; 27(3):158-167. DOI: 10.1016/j.tibtech.2008.11.009.

Elghblawi E. Platelet-rich plasma, the ultimate secret for youthful skin elixir and hair growth triggering. J Cosmet Dermatol. 2018; 17(3):423-430. DOI: 10.1111/jocd.12404.

El-Sharkawy H, Kantarci A, Deady J. Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol. 2007; 78(4):661-669. DOI: 10.1902/jop.2007.060302.

Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg. 2006; 118(6):147-159. DOI: 10.1097/01.prs.0000239606.92676.cf.

Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004; 114(6): 1502-1508. DOI: 10.1097/01.prs.0000138251.07040.51.

Gumucio JP, Sugg KB, Mendias CL. TGF-β superfamily signaling in muscle and tendon adaptation to resistance exercise. Exerc Sport Sci Rev. 2015; 43(2):93-99. DOI: 10.1249/JES.0000000000000041.

James AW, Xu Y, Lee JK, Wang R. Differential effects of TGF-beta1 and TGF-beta 3 on chondrogenesis in posterofrontal cranial suture-derived mesenchymal cells in vitro. Plast Reconstr Surg. 2009; 123(1):31–43. DOI: 10.1097/PRS.0b013e3181904c19.

Klatte-Schulz F, Schmidt T, Uckert M. Comparative Analysis of Different Platelet Lysates and Platelet Rich Preparations to Stimulate Tendon Cell Biology: An In Vitro Study. Int J Mol Sci. 2018; 19(1):1-18. DOI: 10.3390/ijms19010212.

van der Kraan PM. TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis. Osteoarthritis and Cartilage. 2009; 17(12):1539-1545. DOI: 10.1016/j.joca.2009.06.008.

Magalon J, Chateau AL. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med. 2016; 2(1):1-5. DOI: 10.1136/bmjsem-2015-000060.

Perut F, Filardo G. Preparation method and growth factor content of platelet concentrate influence the osteogenic differentiation of bone marrow stromal cells. Cythotherapy. 2013; 15(7):830-839. DOI: 10.1016/j.jcyt.2013.01.220.

Poniatowski LA, Wojdasiewicz P, Gasik R. Transforming growth factor beta family: insight into the role of growth factors in regulation of fracture healing Biology and potential clinical applications. Mediators Inflamm. 2015; 2015:1-15. DOI: 10.1155/2015/137823.

Tuli R, Tuli S, Nandi S, Huang X. Transforming growth factor- -mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogenactivated protein kinase and Wnt signaling cross-talk. J Biol Chem. 2003; 278(42):41227-41236. DOI: 10.1074/jbc.M305312200.

Wang W, Rigueur D, Lyons KM. TGFβ Signaling in Cartilage Development and Maintenance. Birth Defects Res C Embryo Today. 2014; 102(1):37-51. DOI: 10.1002/jbmr.3394.

Weibrich G, Kleis, WK, Hafner G. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg. 2002; 30(2):97-102. DOI: 10.1054/jcms.2002.0285.

Cherian JJ, Parvizi J. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee Osteoarthritis Cartilage. 2015; 23(12):2109-2118. DOI: 10.1016/j.joca.2015.06.019.

Lee MC, Ha CW, Elmallah RK A placebo-controlled randomised trial to assess the effect of TGF-ß1-expressing chondrocytes in patients with arthritis of the knee.Bone Joint J. 2015; 97B(7):924-932. DOI: 10.1302/0301-620X.97B7.35852.

Fang D, Jin P, Huang Q. Platelet-rich plasma promotes the regeneration of cartilage engineered by mesenchymal stem cells and collagen hydrogel via the TGF-β/SMAD signaling pathway. J Cell Physiol. 2019; 234(9):15627-15637 DOI: 10.1002/jcp.28211

Tang Y, Wu X, Lei W, Pang L. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15(7):757-65. DOI: 10.1038/nm.1979.

Taniguchi Y, Yoshioka T. Growth factor levels in leukocyte-poor platelet-rich plasma and correlations with donor age, gender, and platelets in the Japanese population l. Journal of Experimental Orthopaedics. 2019; 6:4. DOI: 10.1186/s40634-019-0175-7.

Evanson JR, Guyton MK., Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. Mil Med. 2014; 179(7):799-805. DOI: 10.7205/MILMED-D-13-00336.